Immunotherapy in GU Cancers Articles

Novel BISCAY Trial Looks Toward Future of Bladder Cancer Treatment
Thomas Powles, MD, MBBS, MRCP, discusses the rationale for the BISCAY trial and what questions still need to be answered. 
Nivolumab/Tivozanib Combo Shows Promise in mRCC
Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.
EU Panel Backs Avelumab/Axitinib Combo for Frontline RCC
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma. 
Real-World Data With Sipuleucel-T Showcase Promising OS in mCRPC
Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.
Novel Immunotherapy Combos Shake Up Bladder Cancer Paradigm
Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.
Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC
The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatments
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.
By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.
Adding atezolizumab to platinum-based chemotherapy significantly improved progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to results from the phase III IMvigor130 study.
 
EU Panel Backs Pembrolizumab Plus Axitinib for Frontline RCC
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
Publication Bottom Border
Border Publication
x